financetom
Business
financetom
/
Business
/
Looking At Target's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Target's Recent Unusual Options Activity
Jan 14, 2025 10:07 AM

Whales with a lot of money to spend have taken a noticeably bearish stance on Target ( TGT ).

Looking at options history for Target ( TGT ) we detected 34 trades.

If we consider the specifics of each trade, it is accurate to state that 29% of the investors opened trades with bullish expectations and 64% with bearish.

From the overall spotted trades, 14 are puts, for a total amount of $1,053,002 and 20, calls, for a total amount of $836,773.

Projected Price Targets

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $100.0 to $150.0 for Target ( TGT ) over the recent three months.

Volume & Open Interest Development

In terms of liquidity and interest, the mean open interest for Target ( TGT ) options trades today is 1233.33 with a total volume of 7,597.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Target's ( TGT ) big money trades within a strike price range of $100.0 to $150.0 over the last 30 days.

Target Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
TGT PUT TRADE BULLISH 06/18/26 $5.2 $4.95 $5.0 $100.00 $150.0K 696 300
TGT PUT SWEEP BEARISH 06/18/26 $14.75 $14.55 $14.75 $130.00 $147.5K 347 100
TGT CALL SWEEP BULLISH 09/19/25 $19.45 $19.4 $19.45 $130.00 $116.7K 296 455
TGT PUT SWEEP BULLISH 12/19/25 $21.65 $21.6 $21.6 $150.00 $116.6K 470 2
TGT PUT SWEEP BULLISH 12/19/25 $21.65 $21.6 $21.6 $150.00 $79.9K 470 56

About Target

Target ( TGT ) serves as the nation's seventh-largest retailer, with its strategy predicated on delivering a gratifying in-store shopping experience and a wide product assortment of trendy apparel, home goods, and household essentials at competitive prices. Target's ( TGT ) upscale and stylish image began to carry national merit in the 1990s—a decade in which the brand saw its top line grow threefold to almost $30 billion—and has since cemented itself as a leading US retailer.Today, Target ( TGT ) operates over 1,950 stores in the United States, generates over $100 billion in sales, and fulfills over 2 billion customer orders annually. The firm's vast footprint is typically concentrated in urban and suburban markets as the firm seeks to attract a more affluent consumer base.

Following our analysis of the options activities associated with Target ( TGT ), we pivot to a closer look at the company's own performance.

Target's Current Market Status

Trading volume stands at 1,381,995, with TGT's price down by -1.12%, positioned at $137.21.

RSI indicators show the stock to be may be approaching overbought.

Earnings announcement expected in 49 days.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Target ( TGT ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Genprex Awarded South Korean Patent for Drug Candidate Reqorsa Plus Antibodies to Treat Cancers
Mar 12, 2024
10:51 AM EDT, 03/12/2024 (MT Newswires) -- Genprex ( GNPX ) said Tuesday that South Korea's Patent Office has issued it a patent covering the use of its Reqorsa Immunogene Therapy lead drug candidate in combination with anti-PD-1 and PD-L1 antibodies through 2037 to treat cancers. The patent is applicable to the company's Acclaim-2 and Acclaim-3 trials, Genprex ( GNPX...
Looking At SoFi Techs's Recent Unusual Options Activity
Looking At SoFi Techs's Recent Unusual Options Activity
Mar 12, 2024
Investors with a lot of money to spend have taken a bearish stance on SoFi Techs . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with...
OneSpaWorld Signs Service Agreements With Celebrity Cruises, Royal Caribbean International
OneSpaWorld Signs Service Agreements With Celebrity Cruises, Royal Caribbean International
Mar 12, 2024
10:47 AM EDT, 03/12/2024 (MT Newswires) -- OneSpaWorld Holdings ( OSWWF ) said Tuesday it signed new multi-year agreements with Celebrity Cruises and Royal Caribbean Group's (RCL) Royal Caribbean International unit to provide its services across Celebrity Cruises and Royal Caribbean fleets. The company said the deals will cover wellness, beauty, acupuncture, medi-spa, and fitness services. No financial details were...
Boeing whistleblower found dead of apparent suicide
Boeing whistleblower found dead of apparent suicide
Mar 12, 2024
(Reuters) - John Barnett, a former Boeing employee who had reportedly raised concerns about the company's production issues, was found dead of an apparent suicide, according to authorities in South Carolina. Barnett had worked at Boeing ( BA ) for 32 years before leaving the company in 2017, according to the BBC, which previously reported on his efforts to raise...
Copyright 2023-2026 - www.financetom.com All Rights Reserved